Stay updated with breaking news from Ryan Saadi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
METUCHEN, N.J.--(BUSINESS WIRE)--#biotech--Tevogen Bio today announced TVGN-489, its lead investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTL) immunotherapy for treatment of COVID-19 in high-risk patients, is expected to retain activity against the B.1.1.529, or Omicron variant. A compre...
Share this article Share this article METUCHEN, N.J., Jan. 25, 2021 /PRNewswire/ -- Tevogen Bio today announced it has secured necessary funding from HMP Partners of New Jersey, an investment firm managed by medical doctors, which will allow Tevogen to support all clinical trials of its investigational, potentially curative COVID-19 treatment. Tevogen's Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the U.S. Food and Drug Administration (FDA). All COVID-19 therapeutics utilized to date have sought to slow the progression of th...